ReproNovo, a clinical-stage biopharmaceutical company committed to addressing critical gaps in male and female fertility as well as women’s health, today announced that the first participant has been dosed in the Company’s EU Phase 2 clinical trial of RPN-002, entitled Nolasiban Optimized Regimen Dosing for Inhibition of Uterine Contractility (NORDIC).